iRemedy Supply

America's healthcare supply chain has a vulnerability most people don't know about — and our CEO Tony Paquin is talking about it openly.

In his recent appearance on the Legal S**t Podcast, Tony joins attorneys Timothy Schulz and Antoinette Wilks to discuss what he witnessed firsthand during COVID-19: fraud, supply chain chaos, foreign manufacturing dependence, and the hard questions America still hasn't answered.

It's a conversation rooted in his book, The End of Us: A Story of Death, Deception and China's Deadly Grip on U.S. Healthcare — and it's one every business leader and policymaker should hear.

Watch the full episode here: https://youtu.be/C5F4zoVtY5A?si=vEDsU7kAlB0tVtOd

Paquin

📚 The End of Us: Is America’s Healthcare System Too Dependent on China? In this episode of Legal S**t, we are here with Tony Paquin, author...

We're glad to have Alex Perdomo on the team. 👋

Alex joins iRemedy as Controller, where he'll be leading our financial close process, supporting SEC filings, and developing our accounting team.

He brings serious credentials — a CPA with dual bachelor's degrees in accounting and MIS and a master's in taxation from FIU.

Outside of work, you'll find him hiking, volunteering with Scouting America and his local Kiwanis club, and spending time with his family.

Welcome, Alex!

We're welcoming Saul Factor to the iRemedy Board of Directors. Saul spent over 30 years at the center of pharmaceutical distribution — including as President of Global Sourcing at McKesson, the largest pharma distributor in the U.S., where he scaled the North Star generics platform to $500M.

He also brings public-company board experience as an independent director of Richtech Robotics (Nasdaq: RR).

His appointment comes as iRemedy moves toward a NASDAQ listing and continues expanding across distribution, specialty biologics, pharmaceutical AI, and federal procurement.

Full press release in the link below:

iRemedy Appoints Former McKesson Global Sourcing President to Its Board Saul Factor, former McKesson Global Sourcing President who scaled North Star generics to $1.5B, joins iRemedy's Board ahead of NASDAQ listing

Happy Birthday, Amanda! 🎂

Grateful to have you on the iRemedy team — here's to a great day and an even better year ahead.

This fraud persisted because no one had the tools to see through it. iRemedy built those tools.

iRemedy's AI platform synthesized bills of lading, UN Comtrade data, FDA regulatory filings, corporate ownership records, and peer-reviewed scientific literature across all 84 essential medicines simultaneously.

Four layers. 84 medicines. Every dependency scored and mapped.

The first assessment that shows — medicine by medicine — where the fraud is, how deep it goes, and who benefits from the concealment.

https://iremedy.com/essential-medicines

🚨 iRemedy just released a first-of-its-kind AI analysis of all 84 medicines the U.S. government designates as essential.

The finding: 89% show significant dependency on Chinese supply chains — not just at the finished product level, but at the raw material level that labels are designed to hide.

• 75 of 84 essential medicines trace back to China at one or more supply chain tiers

• 31 have at least one U.S.-marketed product linked to a Chinese state-affiliated manufacturer

• 85%+ of the β-lactam antibiotic nucleus (amoxicillin, ceftriaxone) is Chinese-origin

• Only 9 of 84 medicines are structurally independent of Chinese supply chains

"The American people are being told their medicines come from trusted, diversified sources. They don't." — Tony Paquin, Founder & CEO

📰 Read the full press release:
https://www.einpresswire.com/article/913466656/iremedy-releases-ai-powered-foreign-dependency-assessment-of-america-s-essential-medicines

📊 Full report medicine by medicine:
https://iremedy.com/essential-medicines